Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myeloid LeukemiaAcquisition brings ...

Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...

Andy Thorn joins the committee with more than 30 years in the BEMS industry, having held roles at Trend, Honeywell, and now Synapsys, where he became Managing Director in 2023. A long-time BCIA member ...

New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared to ...

Not everyone agrees on who is to blame for Kanpur’s decline. Even RSS-backed trade unions don’t rush to blame the striking ...

For the BCIA, 2025 has been a thoroughly successful and positive year. With more than 270 apprentices on its Level 4 Building ...

Advancing toward OEM readiness through advanced vehicle program evaluation; targets up to ~1,000 km EV range.LAS VEGAS, Jan. 6, 2026 /PRNewswire/ -- ...

New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared to placebo in women during menopausal transition ageBrigham and Women's Hospital t ...

Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.

Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...

Clarivate Plc , a leading global provider of transformative intelligence, today released its 2026 Drugs to Watch report, identifying eleven therapies expected to deliver significant clinical impact ...